Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by the degeneration of spinal motor neurons. This disease is mainly caused by mutation or deletion of the survival motor neuron 1 (SMN1) gene. Currently, no effective treatment is available, and only symptomatic treatment can be provided. Our purpose in the present study was to establish a human SMA-derived induced pluripotent stem cell (SMA-iPSC) disease model and assay a therapeutic drug in preparation for the development of a novel treatment of SMA. We generated iPSCs from the skin fibroblasts of a patient with SMA and confirmed that they were pluripotent and undifferentiated. The neural differentiation of SMA-iPSCs shortened the dendrite and axon length and increased the apoptosis of the spinal motor neurons. In addition, we found activated astrocytes in differentiated SMA-iPSCs. Using this model, we confirmed that treatment with the thyrotropin-releasing hormone (TRH) analog, 5-oxo-l-prolyl-l-histidyl-l-prolinamide, which had marginal effects in clinical trials, increases the SMN protein level. This increase was mediated through the transcriptional activation of the SMN2 gene and inhibition of glycogen synthase kinase-3β activity. Finally, the TRH analog treatment resulted in dendrite and axon development of spinal motor neurons in differentiated SMA-iPSCs. These results suggest that this human in vitro disease model stimulates SMA pathology and reveal the potential efficacy of TRH analog treatment for SMA. Therefore, we can screen novel therapeutic drugs such as TRH for SMA easily and effectively using the human SMA-iPSC model. Significance: Platelet-derived growth factor (PDGF) has recently been reported to produce the greatest increase in survival motor neuron protein levels by inhibiting glycogen synthase kinase (GSK)-3β; however, motor neurons lack PDGF receptors. A human in vitro spinal muscular atrophy-derived induced pluripotent stem cell model was established, which showed that the thyrotropin releasing hormone (TRH) analog promoted transcriptional activation of the SMN2 gene and inhibition of GSK-3β activity, resulting in the increase and stabilization of the SMN protein and axon elongation of spinal motor neurons. These results reveal the potential efficacy of TRH analog treatment for SMA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ohuchi et al., 2006, first used SMA patient iPSC-derived motor neurons and astrocytes to show the role of the thyrotropin-releasing hormone analog for the treatment of SMA, which has been taken to clinical trials and showed the potential efficacy of this drug for the treatment of SMA [51].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of this technology in drug discovery has allowed the identification of many new compounds for the potential treatment of various diseases including Zika virus [66], SMA [51], as well as understanding cellular processes and developmental stages using genome editing strategies [72].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
A more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Directed differentiation of telencephalic precursors from embryonic stem cells
Watanabe, K., Kamiya, D., Nishiyama, A., Katayama, T., Nozaki, S., Kawasaki, H., Watanabe, Y., Mizuseki, K., & Sasai, Y. (2005) · Nature Neuroscience · doi:10.1038/nn1402 · Cited by 787
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
The survival motor neuron protein in spinal muscular atrophy
Coovert, D. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1205 · Cited by 714
Jackson, I. M. D. (1982) · New England Journal of Medicine · doi:10.1056/nejm198201213060305 · Cited by 674
Cited by
Vulnerability of Purkinje Cells Generated from Spinocerebellar Ataxia Type 6 Patient-Derived iPSCs
Ishida, Y., Kawakami, H., Kitajima, H., Nishiyama, A., Sasai, Y., Inoue, H., & Muguruma, K. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.026 · Cited by 125
“Cell Reports 17, 1482–1490, November 1, 2016 1487 (legend on next page) 1488 Cell Reports 17, 1482–1490, November 1, 2016 neurons derived from spinal muscular atrophy-specific iPSCs (Ohuchi et al., 2016).”
Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
Silva, M. C., & Haggarty, S. J. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14012 · Cited by 83
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“SMA iPSC-derived neurons are not only used in the pathogenic investigation but also in therapeutic discovery.”
MethodInfluentialBarral, S., & Kurian, M. A. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00078 · Cited by 44
“…et al. (2015), Liu et al. (2015), Ng et al. (2015), Fuller et al. (2016), Heesen et al. (2016) and Patitucci and Ebert (2016) Sareen et al. (2012), Ohuchi et al. (2016) and Xu et al. (2016) Corti et al. (2012), Nizzardo et al. (2015) and Yoshida et al. (2015) et al., 2012); oligodendrocytes…”
Sabitha, K. R., Shetty, A. K., & Upadhya, D. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.025 · Cited by 60
“Reduced dendritic and axonal length with increased selective motor neuron death, a defect mimicking disease phenotype has been recapitulated in motor neurons generated SMA-iPSCs (Ebert et al., 2009; Chang et al., 2011; Ohuchi et al., 2016; Son et al., 2019).”
BackgroundInfluential
Metadata
- Authors
- Ohuchi, K., Funato, M., Kato, Z., Seki, J., Kawase, C., Tamai, Y., Ono, Y., Nagahara, Y., Noda, Y., Kameyama, T., Ando, S., Tsuruma, K., Shimazawa, M., Hara, H., & Kaneko, H.
- Affiliations
- Gifu Pharmaceutical University (JP)
- Nagara Medical Center (JP)
- Gifu University (JP)
- Corresponding author
- Funato, Michinori
- ORCID
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12-18
- Volume
- 5
- Issue
- 2
- Pages
- 152-163
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- PMC
- PMC4729546
- OpenAlex
- W2207092742
- Cited by
- 34
- References
- 41
- Citations by year
- 2025: 5 · 2023: 4 · 2022: 1 · 2021: 1 · 2020: 5 · 2019: 9 · 2018: 3 · 2017: 1 · 2016: 5
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells Translational Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Takeda Science Foundation
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, thyrotropin-releasing hormone analog, SMN1, SMN2, glycogen synthase kinase-3β, motor neuron differentiation, axon elongation, dendrite formation, astrocytes, drug screening, platelet-derived growth factor
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Astrocytes, Cell Differentiation, Child, Preschool, Female, Fibroblasts, Humans, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Spine, Thyrotropin-Releasing Hormone, Signal Transduction, Transcriptional Activation, Gene Expression, Apoptosis, Glycogen Synthase Kinase 3, Survival of Motor Neuron 1 Protein, Survival of Motor Neuron 2 Protein, Induced Pluripotent Stem Cells, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog. https://app.cochat.ai/papers/10.5966/sctm.2015-0059
- The paper
- Ohuchi, K., Funato, M., Kato, Z., Seki, J., Kawase, C., Tamai, Y., Ono, Y., Nagahara, Y., Noda, Y., Kameyama, T., Ando, S., Tsuruma, K., Shimazawa, M., Hara, H., & Kaneko, H. (2016). Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog. Stem Cells Translational Medicine. https://doi.org/10.5966/sctm.2015-0059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.